
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune is a biopharmaceutical company that is primarily focused on developing precision medicine treatments for neurodegenerative diseases. They have a diverse pipeline of programs targeting misfolded proteins, including ACI-24, Crenezumab, ACI-35, Semorinemab, and ACI-7104. The company recently reported positive financial results for the first quarter of 2026, with a decrease in R&D expenses and a significant increase in total cash resources. They have upcoming catalysts, including the release of data for the ACI-24 vaccine in Alzheimer's disease and the potential exercise of an option by Takeda for ACI-24, which could provide a substantial source of revenue. Additionally, they are exploring partnerships for their ongoing clinical and discovery programs, which could further bolster their financial position. Overall, AC Immune's innovative approach to targeting neurodegenerative diseases and their strong financial standing make the company a promising investment opportunity.
Bears say
AC Immune is currently heavily reliant on its pipeline of misfolded protein targeting therapies, which face technical and biological risks as they are based on educated guesses of toxic species structure and lack significant evidence of cognitive benefit in Parkinson's Disease (PD). Additionally, its AD program appears to be more de-risked than PD due to the established link between plaque clearance and cognitive benefit, as well as a better-established readout through PET scans compared to the semi-quantitative measurement used for aSyn aggregates. The company's future success is therefore uncertain and dependent on the success of its pipeline.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares